Skip to content

4th Annual MS Lung Cancer Roundtable Meeting - November 7-8, 2025

1.Please select which of the following best describes your primary role.
2.On a scale of 1 to 5, with 1 being NOT SATISFIED and 5 being VERY SATISFIED, please rate your level of satisfaction with each of the following:
1 - Not Satisfied
2 - Somewhat satisfied
3 - Neutral
4 - Satisfied
5 - Very Satisfied
Relevance of information to your needs.
Presentation quality of instructor(s).
Subject matter knowledge of instructor(s).
Training facilities or webinar platform.
Instructor's engagement and response to questions.
Overall quality of the training/workshop.
3.General Sessions
On a scale of 1 to 5, with 1 being VERY LOW and 5 being VERY HIGH, please rate your level of knowledge about each of the following BEFORE the training.
1 - Very Low
2 - Low
3 - Moderate
4 - High
5 - Very High
The ability to recognize the personal and psychosocial impacts of a lung cancer diagnosis and treatment from the patient perspective.
Update on screening for lung cancer in the U.S.
Challenges in uptake, adherence, and disparities.
The role of tobacco cessation in improving outcomes across the cancer continuum, including prevention, screening, diagnosis, treatment, recovery and survivorship.
Evidence-based tobacco treatment strategies and apply them to example clinical scenarios in cancer care.
The applications of AI in detection of those at risk for lung cancer.
The applications of AI in stratification of those at risk for lung cancer.
The SYBIL model for predicting future lung cancer risk.
Integration of the SYBIL model into lung cancer screening and risk assessment strategies.
4.General Sessions
On a scale of 1 to 5, with 1 being VERY LOW and 5 being VERY HIGH, please rate your level of knowledge about each of the following AFTER the training.
1 - Very Low
2 - Low
3 - Moderate
4 - High
5 - Very High
The ability to recognize the personal and psychosocial impacts of a lung cancer diagnosis and treatment from the patient perspective.
Update on screening for lung cancer in the U.S.
Challenges in uptake, adherence, and disparities.
The role of tobacco cessation in improving outcomes across the cancer continuum, including prevention, screening, diagnosis, treatment, recovery and survivorship.
Evidence-based tobacco treatment strategies and apply them to example clinical scenarios in cancer care.
The applications of AI in detection of those at risk for lung cancer.
The applications of AI in stratification of those at risk for lung cancer.
The SYBIL model for predicting future lung cancer risk.
Integration of the SYBIL model into lung cancer screening and risk assessment strategies.
5.HEALTH PROFESSIONAL TRACK
On a scale of 1 to 5, with 1 being VERY LOW and 5 being VERY HIGH, please rate your level of knowledge about each of the following BEFORE the training.
1 - Very Low
2 - Low
3 - Moderate
4 - High
5 - Very High
The recent advances in the identification and characterization of oncogene-driven mutations in early-stage non–small cell lung cancer (NSCLC).
The latest evidence supporting the use of targeted therapies and perioperative treatment strategies in early-stage oncogene-driven NSCLC.
Key imaging and clinical features that help differentiate benign from malignant pulmonary nodules.
Current evidence-based guidelines used to evaluate and manage patients with pulmonary nodules.
The current standard of care and guidelines for staging of SCLC
The role of surgery in SCLC.
The new systemic therapy options for small cell lung cancer patients.
Patient characteristics used to guide treatment with tarlatamab bispecific antibody therapy.
6.HEALTH PROFESSIONAL TRACK
On a scale of 1 to 5, with 1 being VERY LOW and 5 being VERY HIGH, please rate your level of knowledge about each of the following AFTER the training.
1 - Very Low
2 - Low
3 - Moderate
4 - High
5 - Very High
The recent advances in the identification and characterization of oncogene-driven mutations in early-stage non–small cell lung cancer (NSCLC).
The latest evidence supporting the use of targeted therapies and perioperative treatment strategies in early-stage oncogene-driven NSCLC.
Key imaging and clinical features that help differentiate benign from malignant pulmonary nodules.
Current evidence-based guidelines used to evaluate and manage patients with pulmonary nodules.
The current standard of care and guidelines for staging of SCLC
The role of surgery in SCLC.
The new systemic therapy options for small cell lung cancer patients.
Patient characteristics used to guide treatment with tarlatamab bispecific antibody therapy.
7.COMMUNITY TRACK
On a scale of 1 to 5, with 1 being VERY LOW and 5 being VERY HIGH, please rate your level of knowledge about each of the following BEFORE the training.
1 - Very Low
2 - Low
3 - Moderate
4 - High
5 - Very High
Communicating lung cancer prevention messages to diverse communities.
Culturally responsive approaches to community engagement and health communication.
Successful models of collaboration between community organizations and healthcare providers to address disparities.
The barriers that prevent communities from accessing lung cancer care and resources.
Grassroots and statewide initiatives that improve trust and access.
The tools, programs, and partnerships available that support Mississippi communities.
The collaborative models across the lung cancer continuum.
8.COMMUNITY TRACK
On a scale of 1 to 5, with 1 being VERY LOW and 5 being VERY HIGH, please rate your level of knowledge about each of the following AFTER the training.
1 - Very Low
2 - Low
3 - Moderate
4 - High
5 - Very High
Communicating lung cancer prevention messages to diverse communities.
Culturally responsive approaches to community engagement and health communication.
Successful models of collaboration between community organizations and healthcare providers to address disparities.
The barriers that prevent communities from accessing lung cancer care and resources.
Grassroots and statewide initiatives that improve trust and access.
The tools, programs, and partnerships available that support Mississippi communities.
The collaborative models across the lung cancer continuum.
9.On a scale of 1 to 5, with 1 being NOT AT ALL LIKELY and 5 being EXTREMELY LIKELY, please rate how likely you are to do each of the following as a result of this training/workshop.
1 - Not At All Likely
2 - Unlikel
3 - Undecided
4 - Likely
5 - Extremely Likely
Apply information from this workshop/training in your organization
Achieve the goals stated in this training/workshop
Share this information with others within your organization
Develop a plan to implement the desired change within your organization
Attend other trainings related to this topic
10.What actions do you plan to take to implement the knowledge you gained today?
11.Did you detect any commercial bias?
12.What did you like best about the 4th Annual MS Lung Cancer Roundtable?
13.What can we do better or what was missing from the 4th Annual MS Lung Cancer Roundtable Meeting?
14.Is there any other feedback you would like to share?
Current Progress,
0 of 18 answered